TISSUE DOSIMETRY, PHARMACOKINETIC MODELING, AND INTERSPECIES SCALING FACTORS

被引:30
作者
ANDERSEN, ME
CLEWELL, H
KRISHNAN, K
机构
[1] ICF KAISER ENGINEERS,RUSTON,LA
[2] UNIV MONTREAL,MONTREAL,PQ H3C 3J7,CANADA
关键词
INTERSPECIES SCALING FACTORS; PHARMACOKINETICS; TISSUE DOSIMETRY; TISSUE SENSITIVITY; DEFAULT PROCEDURES; PHARMACODYNAMICS;
D O I
10.1111/j.1539-6924.1995.tb00346.x
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Interspecies scaling factors (ISFs) are numbers used to adjust the potency factor (for example, the ql* for carcinogens or reference doses for compounds eliciting other toxic endpoints) determined in experimental animals to account for expected differences in potency between test animals and people. ISFs have been developed for both cancer and non-cancer risk assessments in response to a common issue: toxicologists often determine adverse effects of chemicals in test animals and then they, or more commonly risk assessors and risk managers, have to draw inferences about what these observations mean for the human population. This perspective briefly reviews the development of ISFs and their applications in health risk assessments over the past 20 years, examining the impact of pharmacokinetic principles in altering current perceptions of the ISFs applied in these health risk assessments, and assessing future directions in applying both pharmacokinetic and pharmacodynamic principles for developing ISFs.
引用
收藏
页码:533 / 537
页数:5
相关论文
共 25 条
[1]   PHYSIOLOGICALLY BASED PHARMACOKINETICS AND THE RISK ASSESSMENT PROCESS FOR METHYLENE-CHLORIDE [J].
ANDERSEN, ME ;
CLEWELL, HJ ;
GARGAS, ML ;
SMITH, FA ;
REITZ, RH .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 1987, 87 (02) :185-205
[2]   SATURABLE METABOLISM AND ITS RELATIONSHIP TO TOXICITY [J].
ANDERSEN, ME .
CRC CRITICAL REVIEWS IN TOXICOLOGY, 1981, 9 (02) :105-150
[3]  
ANDERSEN ME, 1995, ALTERNATIVE METHODS, V20
[4]   REFERENCE DOSE (RFD) - DESCRIPTION AND USE IN HEALTH RISK ASSESSMENTS [J].
BARNES, DG ;
DOURSON, M .
REGULATORY TOXICOLOGY AND PHARMACOLOGY, 1988, 8 (04) :471-486
[5]  
*CAN HLTH, 1993, PRIOR SUBST LIST ASS
[6]  
Clewell H J 3rd, 1985, Toxicol Ind Health, V1, P111
[7]   INCORPORATION OF PHARMACOKINETICS IN NONCANCER RISK ASSESSMENT - EXAMPLE WITH CHLOROPENTAFLUOROBENZENE [J].
CLEWELL, HJ ;
JARNOT, BM .
RISK ANALYSIS, 1994, 14 (03) :265-276
[8]   COUPLING OF COMPUTER MODELING WITH INVITRO METHODOLOGIES TO REDUCE ANIMAL USAGE IN TOXICITY TESTING [J].
CLEWELL, HJ .
TOXICOLOGY LETTERS, 1993, 68 (1-2) :101-117
[9]  
Dourson M L, 1983, Regul Toxicol Pharmacol, V3, P224, DOI 10.1016/0273-2300(83)90030-2
[10]  
FREIREICH EJ, 1966, CANCER CHEMOTH REP, V50, P19